Lava Therapeutics has jettisoned its only wholly owned clinical-stage asset after the blood cancer drug “did not reach Lava’s internal benchmarks.”

The Dutch biotech had been evaluating the candidate, dubbed LAVA-1207, in a phase 1 trial for prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer (mCRPC).